Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Biomodulina T + CIMAvax-EGF
- Development stage
- Preclinical
- Lead developer
- Center for Molecular Immunology
- Modality
- Peptides, Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
Biomodulina T is a thymic polypeptide fraction with immunomodulatory properties, while CIMAvax-EGF is an epidermal growth factor (EGF)-depleting immunotherapy vaccine. The combination involves sequential administration of Biomodulina T followed by CIMAvax-EGF. This approach aims to restore immune function after chemotherapy in advanced non-small cell lung cancer (NSCLC) patients and enhance the immune response to the EGF-targeting vaccine. The mechanism of action for this combination includes immunorestoration by Biomodulina T, which may decrease exhausted and terminally differentiated EMRA T cells, followed by induction of anti-EGF antibodies via CIMAvax-EGF vaccination. These antibodies reduce circulating EGF levels, thereby depriving cancer cells of a key growth signal[1][9][6].
- Other names
- BT + CIMAvax-EGFBiomodulina T and CIMAvax-EGF
Beyond the preview
Go deeper on Biomodulina T + CIMAvax-EGF.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Biomodulina T + CIMAvax-EGF.